Metformin HCl Tablets

Active Ingredients: Metformin HCl

Metformin HCl Tablets are a drug used as a first-line therapy in the treatment of diabetes mellitus (type 2 diabetes). It is used in combination with a diet and exercise program. This drug may be used as monotherapy or with other antidiabetic medications. It is not used to treat type 1 diabetes.

Metformin hydrochloride is a member of the biguanide class of antihyperglycemics. It works by decreasing glucose absorption from food, reducing the amount of glucose made in the liver, and increasing the body's response to insulin. This drug works by lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production and intestinal glucose absorption which all improves insulin sensitivity. This medication does not cause hypoglycemia and hyperinsulinemia.

The bioavailability of a 500mg tablet in fasting conditions is around 50-60%, while food delays the absorption. When distributed, this drug is 90% protein-bound and it partitions into erythrocytes. After oral intake, around 90% of the drug is eliminated via the renal route within the first 24 hours, and the plasma elimination half-life is approximately 6.2 hours.

AdvaCare Pharma's Metformin HCl Tablets are manufactured in GMP-certified facilities located in China, India, and the USA. We routinely inspect our production facilities to ensure our products meet health, safety, and environmental standards.

AdvaCare Pharma is a manufacturer of Metformin Tablets and other cost-effective and sustainable pharmaceuticals for an ever-changing global market. Metformin Tablets are a GMP-compliant medicine that is available for distribution.

As a leading Metformin manufacturer, we work with international partners including pharmaceutical distributors, hospitals, pharmacies and other medical and government organizations. We have established a vested supplier-distributor relationship, ensuring a mutually advantageous outcome during market entry and development.

What is Metformin HCl used for?

It is used to treat high blood sugar in people with type 2 diabetes.

How are Metformin HCl Tablets used?

This medication is intended to be taken orally.

What dose should be taken?

The usual dose for adults is 500mg, taken twice per day or 850mg once a day.

There are no defined dosage recommendations for pediatric and geriatric patients.

The dosage is based on medical condition, response to treatment, age, and weight. Refer to a doctor or pharmacist for guidelines on dosage. Do not exceed what they advise.

Who can take Metformin HCl?

Metformin HCl can be used by patients for managing type 2 diabetes. Special consideration should be made when giving this drug to certain patient categories.

Pregnant Abnormal blood glucose levels during pregnancy are due to a higher incidence of congenital abnormalities. Healthcare providers advise using insulin during pregnancy to maintain normal blood glucose levels. Metformin HCl should be used during pregnancy only when clearly needed. There are no adequate and well-controlled studies in pregnant women that approve the usage of Metformin HCl. Consult with a healthcare provider if you are pregnant or planning to get pregnant before using this medication.

Nursing This medicament is excreted into milk as confirmed by animal studies and it reaches levels comparable to those in plasma. Hypoglycemia in nursing infants occurs and doctors should make a good conclusion on whether to continue or discontinue this drug during nursing. Consult with a doctor if you are a good candidate to use this drug during breastfeeding.

Pediatric It can be safely used in pediatric patients aged from 10 to 16 years and no studies have been performed in patients below the age of 10 years. The usage of this drug in patients from 10 to 16 years shows that it is safe and efficacious and shows similar effects as that seen in adults.

Geriatric Metformin HCl in older adults shows a similar response as that in adults. There are no significant differences in responses between the elderly and younger patients. This drug is excreted through the kidney and special consideration should be made when giving it to patients with impaired renal function. The dose should be also based on the renal function.

What should be done in cases of Metformin HCl overdose?

Overdosing usually occurs when taking Metformin HCl in amounts greater than 50g. Hypoglycemia occurs in around 10% of cases of overdosing but no causal association exists. This hypoglycemia is a side effect and it is severe in cases of overdose of this medication. Lactic acidosis occurs in around 32% of metformin overdose cases. Hemodialysis is the best approach to remove the accumulated drug from patients where metformin overdose is suspected.

Is only Metformin HCl enough to treat patients with type 2 diabetes?

It depends on the severity of the cause. Very often, it is the first-line medication for treating type 2 diabetes. It can reduce the amount of glucose produced by the liver and improve the body’s response to insulin.

The treatment plan depends on the severity of the disease and the individual response. Patients are also advised to consume a healthy and well-balanced diet and maintain a regular exercise program to manage this condition.

Can people with heart failure take metformin?

Heart failure does not automatically exclude the use of metformin. The 2026 Standards of Care in Diabetes state that metformin may be continued for glucose lowering in people with type 2 diabetes and stable heart failure when estimated glomerular filtration rate (eGFR) remains above 30mL/min/1.73m². It should be avoided in unstable or hospitalized patients with heart failure.

Acute or worsening heart failure associated with poor tissue perfusion or low blood oxygen can increase the risk of metformin-associated lactic acidosis. Treatment should therefore be individualized according to renal function, clinical stability and the prescribing information approved in the relevant market.

Does metformin improve heart failure outcomes?

Metformin is used to improve glycemic control in people with type 2 diabetes; it is not an approved treatment for heart failure.

In the 2026 Met-HeFT randomized trial, 940 patients with symptomatic heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes, prediabetes or increased diabetes risk received metformin or placebo. After a mean follow-up of 3.7 years, metformin did not significantly reduce the combined risk of death, worsening heart failure, acute myocardial infarction or stroke compared with placebo.

The findings do not support an independent cardioprotective effect of metformin in HFrEF. They should not be interpreted as establishing a new heart-failure indication for metformin.

Because the Met-HeFT results were presented at ESC Congress 2026 and a full peer-reviewed results publication was not identified at the time of this review, the findings should be described as newly reported randomized evidence pending full publication.

Other warnings

Metformin-associated lactic acidosis is a rare but serious complication. Risk is increased when metformin accumulates or when other conditions impair lactate metabolism, particularly significant renal impairment, acute cardiorespiratory illness, sepsis, shock, tissue hypoxia, excessive alcohol intake or hepatic impairment.

Renal function should be assessed using estimated glomerular filtration rate (eGFR) before treatment and periodically during therapy. Metformin HCl Tablets are contraindicated in patients with an eGFR below 30mL/min/1.73m². Initiating treatment is generally not recommended when eGFR is between 30 and 45mL/min/1.73m².

Acute congestive heart failure accompanied by hypoperfusion or hypoxemia may increase the risk of lactic acidosis. Metformin should be discontinued when such an acute hypoxic event occurs. This differs from stable chronic heart failure, in which metformin may remain an option for glucose lowering when renal function and the patient's clinical condition are appropriate.

Metformin may need to be temporarily withheld for certain iodinated contrast imaging procedures and during surgical or other procedures involving restricted food and fluid intake. Renal function should be reassessed when clinically appropriate before treatment is resumed.

Patients should avoid excessive alcohol intake while taking metformin because alcohol can increase its effects on lactate metabolism.

When metformin is used with insulin or medicines that stimulate insulin secretion, the risk of hypoglycemia may increase and adjustment of the other glucose-lowering medicine may be necessary.

As with all pharmaceuticals, some unwanted effects can occur from the use of Metformin HCl Tablets.

For a comprehensive understanding of all potential side effects, consult a medical professional.

If any symptoms persist or worsen, or you notice any other symptoms, please call your doctor immediately.

Metformin-associated lactic acidosis is rare but serious. The risk is increased in certain clinical circumstances, including significant renal impairment, acute hypoxic states, severe infection or shock, excessive alcohol intake, hepatic impairment, and some surgical or radiological procedures.

Heart failure is not necessarily a contraindication to metformin in every patient. In people with stable heart failure, use should be assessed according to renal function, clinical status and the locally approved prescribing information. Metformin should be avoided or discontinued when acute or worsening heart failure is associated with hypoperfusion, hypoxemia or other conditions that increase the risk of lactic acidosis.

Renal function should be assessed before treatment and periodically thereafter. Initiation of metformin is generally not recommended when eGFR is between 30 and 45mL/min/1.73m², and treatment should be discontinued if eGFR falls below 30mL/min/1.73m².

Concomitant treatment with insulin or an insulin secretagogue is not an absolute contraindication to metformin, but it may increase the risk of hypoglycemia and may require adjustment of the other glucose-lowering medicine.

Metformin may need to be temporarily discontinued in connection with certain iodinated contrast procedures, surgery or other circumstances associated with restricted food or fluid intake, acute renal impairment or tissue hypoxia.

Contraindications and precautions may vary according to the product registration and prescribing information approved in each market. Patients should follow the advice of a qualified healthcare professional.

Met-HeFT: Metformin and Chronic Heart Failure — ESC Congress 2026

The European Society of Cardiology reported results from the Met-HeFT randomized, double-blind, placebo-controlled trial evaluating whether metformin provides cardiovascular benefit in patients with symptomatic heart failure with reduced ejection fraction (HFrEF) and diabetes or increased diabetes risk.

A total of 940 participants were randomized to metformin or placebo and followed for a mean of 3.7 years. The primary composite outcome of death, worsening heart failure, acute myocardial infarction or stroke occurred in 25.1% of the metformin group and 23.4% of the placebo group, with no statistically significant difference.

The findings did not demonstrate an independent cardiovascular benefit of metformin in this HFrEF population. ESC reported that metformin was not associated with evidence of harm in the trial and continues to have an established role in glucose lowering. Approximately 10% of participants had established type 2 diabetes, which limits generalization to the wider diabetic population.

Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026

The American Diabetes Association's 2026 Standards of Care provide current recommendations for managing cardiovascular disease and heart failure in people with diabetes.

For people with type 2 diabetes and stable heart failure, the guideline states that metformin may be continued for glucose lowering when eGFR remains above 30mL/min/1.73m². Metformin should be avoided in unstable or hospitalized individuals with heart failure. The guideline also emphasizes therapies with specifically demonstrated heart-failure outcome benefits when cardiovascular risk reduction is required.

Metformin Hydrochloride Tablets — Prescribing Information

Current U.S. prescribing information identifies severe renal impairment, hypersensitivity to metformin and acute or chronic metabolic acidosis, including diabetic ketoacidosis, among the principal contraindications to metformin hydrochloride tablets.

The prescribing information also identifies hypoxic states such as acute congestive heart failure—particularly when accompanied by hypoperfusion and hypoxemia—as risk factors for metformin-associated lactic acidosis. Renal function should be assessed using eGFR before treatment and periodically thereafter.

The DANHEART Randomized Trial: H-HeFT and Met-HeFT

This peer-reviewed publication describes the design and rationale of the DANHEART program, including Met-HeFT. The Met-HeFT component was designed as a randomized, double-blind, placebo-controlled study examining cardiovascular outcomes with metformin in patients with symptomatic HFrEF and diabetes or prediabetes.

The publication provides useful peer-reviewed background on the trial methodology and planned cardiovascular endpoints and confirms the ClinicalTrials.gov registration NCT03514108.